.png){kind=icon}
.png){kind=icon}
Return
Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2
.png){kind=icon}
PRE
AI
G
S
M
S
J
B
A
V
C
M
E
N
P
S
M
DOI：10.1016/j.anai.2026.06.011.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Chronic spontaneous urticaria (CSU) substantially reduces patient quality of life (QoL); therefore, it is crucial to include QoL-related patient-reported outcome measures (PROMs) when assessing treatment efficacy.
Journal
A
IF:
0
Papers:
195
Citations:
0
Organization
View more organizations